BioCorp and Roche Diabetes Care France announced the launch of the Mallya smart insulin pen device in France.
Developed by BioCorp, Mallya is an intelligent sensor for insulin injection pens that has CE mark approval in Europe. The platform is compatible with any disposable insulin pen. It enables reliable monitoring for doses selected for injection and it offers patients with diabetes better compliance with their treatment, according to the companies.
The device is designed to automatically collect insulin data (dose, date, time) and transfer it to Roche’s Gluci-Chek application to ensure qualified information on which the patient can rely and the physician can then use to make informed clinical decisions.
Roche’s bases its diabetes management system on connected glucose meters, the Gluci-Chek application and its platform for healthcare professionals in diabetes care, while Mallya adds insulin data for more comprehensive patient monitoring.
Once Mallya and Gluci-Chek are connected, a patient no longer has to report their insulin doses, as the data is automatically displayed in the user’s blood-glucose logbook for any compatible insulin pen.
BioCorp and Roche announced the collaboration in June 2020. The device, which is touted as the first in its category to receive the CE mark, is manufactured in Clermont-Ferrand, France.
“The commercial launch of Mallya represents an important milestone for BioCorp. We are really proud to be leading it with Roche Diabetes Care France,” BioCorp CEO Eric Dessertenne said in a news release. “Its leading position, its vast distribution network in pharmacies and the connection of our innovative device to its Gluci-Chek solution present undeniable benefits for all healthcare professionals but also and above all for diabetic patients looking for a better quality of life, a better comfort in the management and daily follow-up of their disease.”
“For more than 40 years, we have been helping people with diabetes think less about the day-to-day management of their disease. We are committed to the autonomy and quality of life of patients with diabetes, empowering them to understand and act on their condition,” added Roche Diabetes Care France president Frédéric Jacquey. “This is precisely what Mallya allows, when integrated with our digital ecosystem for patients and healthcare professionals. We are currently the only company to offer a quality solution based on a CE-marked medical device.”
